How Much Does Evenity (Romosozumab) Cost in Wyoming in 2026?

Evenity List Price and Cash-Pay Cost in Wyoming

The wholesale acquisition cost (WAC) for Evenity in Wyoming is $1,825 per monthly dose, unchanged from the national Amgen/UCB list price. A complete 12-dose treatment course totals approximately $21,900 before any insurance or discount adjustments. Cash-pay pricing at Wyoming retail pharmacies mirrors this WAC figure because the drug is a specialty biologic distributed through limited channels.

Wyoming has fewer specialty pharmacies than most states. Patients filling without insurance typically encounter the full list price at chains like Albertsons (which operates pharmacy locations across the state) or through specialty mail-order services. The FDA-approved prescribing information specifies romosozumab-aqqg 210 mg subcutaneous injection once monthly, administered as two separate 105 mg/1.17 mL prefilled syringes at a single visit [1].

Price comparison tools like GoodRx show minimal variation across Wyoming ZIP codes because the drug flows through specialty distribution. Patients in Cheyenne, Casper, and Laramie report identical pricing. The 12-month treatment limit built into the FDA label means cost exposure is finite, unlike chronic bisphosphonate therapy that may continue for 5+ years.

Wyoming Medicaid Coverage for Romosozumab

Wyoming Medicaid does not cover Evenity as of 2026. The state's preferred drug list excludes romosozumab, directing Medicaid beneficiaries toward covered alternatives including oral alendronate, zoledronic acid infusion, and denosumab (Prolia).

This exclusion affects a significant population. Wyoming's Medicaid enrollment includes approximately 54,000 adults, and the state has one of the nation's highest rates of osteoporosis-related hip fractures per capita among rural populations. The Endocrine Society's 2020 guidelines recommend romosozumab as first-line therapy for patients at very high fracture risk, defined as those with recent fractures, T-scores below -3.0, or FRAX scores above country-specific intervention thresholds [2].

Patients on Wyoming Medicaid who clinically require romosozumab have limited options. A treating physician can submit a prior authorization exception request documenting bisphosphonate intolerance or failure, though approval rates for such exceptions remain low based on available state data. Switching to Medicare Part B coverage (for dual-eligible patients) may provide a pathway, as Medicare covers Evenity under its Part B injectable drug benefit with appropriate documentation.

Commercial Insurance Coverage in Wyoming

Most commercial plans available in Wyoming cover Evenity under their specialty pharmacy or medical benefit with prior authorization. The prior authorization criteria typically require documentation of postmenopausal status, a DXA T-score of -2.5 or below at the hip or spine, high fracture risk per FRAX calculation, and failure of or contraindication to at least one prior osteoporosis therapy.

Blue Cross Blue Shield of Wyoming, the state's largest commercial insurer, categorizes Evenity as a specialty tier medication. Patient cost-sharing on specialty tiers commonly runs 20-33% coinsurance, translating to $365-$602 per injection before any manufacturer support. UnitedHealthcare and Cigna plans sold through the Wyoming marketplace apply similar tiering.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone at 24 months (Saag et al., NEJM 2017) [3]. Insurance medical directors increasingly recognize this evidence when adjudicating prior authorizations, particularly for patients with recent fragility fractures. Approval rates have climbed since 2022 as real-world fracture prevention data accumulates.

The Amgen/UCB Savings Card: How It Works in Wyoming

The Evenity Together savings program from Amgen and UCB reduces out-of-pocket costs for commercially insured patients in Wyoming. Eligible patients with commercial insurance pay as little as $5 per monthly injection, with the program covering up to $15 to 000 in copay assistance per calendar year.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance that covers Evenity, must not be enrolled in any federal or state healthcare program (Medicare, Medicaid, Tricare, VA), and must be a resident of the United States. Wyoming patients meet geographic eligibility automatically.

The $15,000 annual cap provides meaningful protection. At typical specialty tier coinsurance of 25% ($456/month), the card covers the full 12-month course with room to spare. Patients can enroll online or through their specialty pharmacy at the time of first fill. The card activates at the pharmacy point-of-sale system and applies automatically to each subsequent fill.

One limitation: the savings card does not apply to deductible amounts on high-deductible health plans (HDHPs) in some configurations. Wyoming residents on HDHPs through employers should confirm with the program's support line (1-888-EVENITY) whether their specific plan structure qualifies.

Compounded Romosozumab in Wyoming: Legal Status and Pricing

Compounded romosozumab is legally available in Wyoming through 503A compounding pharmacies that hold valid state licenses. Wyoming Board of Pharmacy regulations permit patient-specific compounding of FDA-approved molecules when a prescriber issues an individual prescription based on a documented medical need.

The practical reality introduces complexity. Romosozumab is a monoclonal antibody produced through recombinant DNA technology in Chinese hamster ovary (CHO) cells. Replicating this biologic through traditional compounding is not pharmacologically feasible with standard compounding equipment. Unlike small-molecule drugs such as testosterone or progesterone that compound readily, monoclonal antibodies require cell culture, purification systems, and quality controls that exist only in full-scale biomanufacturing facilities.

Any entity claiming to compound romosozumab should be examined with extreme caution. The FDA's guidance on biological products distinguishes between mixing/diluting an existing approved product (permissible) and manufacturing a new biologic from raw materials (which requires a Biologics License Application) [4]. Wyoming patients encountering compounded romosozumab offers at dramatically lower prices should verify the pharmacy's 503A registration status with the Wyoming Board of Pharmacy and confirm exactly what product they are receiving.

Telehealth Prescribing of Evenity in Wyoming

Wyoming permits telehealth prescribing of Evenity. The state's telehealth parity laws, updated in 2021, allow licensed physicians to establish patient relationships and prescribe medications via synchronous audio-video visits without requiring a prior in-person encounter.

For romosozumab specifically, the telehealth pathway works best for the prescribing decision, treatment initiation, and monitoring. The subcutaneous injections themselves require either in-office administration or patient self-injection training. Wyoming's rural geography makes telehealth particularly valuable. A patient in Sheridan or Rock Springs can consult with an endocrinologist or rheumatologist in Cheyenne without a 4-hour drive.

The prescribing workflow typically proceeds as follows: the specialist reviews DXA scans (which can be performed at any imaging center), FRAX scores, fracture history, and cardiovascular risk. The FDA's boxed warning requires assessment of cardiovascular risk because the ARCH trial showed a higher rate of major adverse cardiac events with romosozumab versus alendronate (2.5% vs. 1.9% at 12 months) [1]. A telehealth provider can review ECG results, cardiac history, and blood pressure trends transmitted electronically to make this risk determination.

Once prescribed, the specialty pharmacy ships Evenity directly to the patient's home or a local clinic for administration. Some Wyoming patients receive injections at their primary care office while the prescribing specialist manages the case remotely.

How Evenity Compares to Other Osteoporosis Treatments on Cost

Understanding romosozumab's price in context helps Wyoming patients and prescribers make informed formulary decisions. Generic alendronate costs $4-15 per month. Zoledronic acid (Reclast) infusion runs $1,200-1,500 annually. Denosumab (Prolia) costs approximately $1,650 per 6-month injection ($3,300/year). Teriparatide (Forteo) runs approximately $3,500 per month for 24 months of therapy.

Romosozumab at $21,900 for a finite 12-month course sits between Prolia's ongoing cost and Forteo's higher monthly expense. The clinical distinction matters for cost-effectiveness. The FRAME trial (N=7,180) demonstrated 73% relative risk reduction in new vertebral fractures at 12 months with romosozumab versus placebo [3]. No other osteoporosis agent achieves this magnitude of bone formation stimulation in this timeframe.

A cost-effectiveness analysis published in the Journal of Bone and Mineral Research found romosozumab-to-alendronate sequencing cost-effective at a willingness-to-pay threshold of $150,000 per quality-adjusted life year (QALY) for women aged 70+ with T-scores below -3.0 and prior fracture [5]. For Wyoming patients meeting these criteria, the upfront cost may be justified by prevented hospitalizations. Hip fracture hospitalization in Wyoming averages $45,000-65,000, and 12-month post-fracture mortality in patients over 75 exceeds 20% nationally per CDC data [6].

Navigating Prior Authorization in Wyoming

Prior authorization for Evenity in Wyoming follows a predictable pattern across insurers. Prescribers should prepare documentation addressing four domains: diagnosis confirmation, risk stratification, treatment history, and cardiovascular clearance.

Diagnosis confirmation requires a DXA scan showing a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip. Some insurers accept -2.0 with additional risk factors. Risk stratification uses FRAX 10-year probability calculations. A major osteoporotic fracture probability exceeding 20% or hip fracture probability exceeding 3% typically meets threshold criteria.

Treatment history documentation should show failure of, intolerance to, or contraindication for at least one antiresorptive agent. "Failure" usually means a new fracture or continued bone density decline after 12+ months of compliant therapy. The American Association of Clinical Endocrinologists (AACE) 2020 guidelines provide specific criteria for classifying patients as "very high risk" warranting anabolic-first therapy without antiresorptive trial [2].

Cardiovascular clearance addresses the boxed warning. Documenting absence of myocardial infarction or stroke within the preceding year, along with controlled blood pressure and no unstable angina, satisfies most payer requirements.

Appeals for initial denials succeed at rates of approximately 40-60% when the prescriber submits a peer-to-peer review with supporting literature. Wyoming physicians report that including the ARCH trial data and AACE guideline language in appeal letters improves outcomes.

Patient Assistance for Uninsured Wyoming Residents

Wyoming residents without insurance face the full $21,900 course cost. Several assistance pathways exist beyond the savings card (which requires commercial coverage).

The Amgen Safety Net Foundation provides free Evenity to qualifying patients with household incomes below 300% of the federal poverty level ($46,800 for a single individual in 2026). Applications require proof of income, proof of U.S. residency, and documentation that the patient lacks coverage for the drug. Processing takes 2-4 weeks.

The HealthWell Foundation and the National Osteoporosis Foundation occasionally offer copay grants for bone-building therapies, though fund availability fluctuates. Wyoming patients should check eligibility quarterly as funds open and close based on donations.

Hospital financial assistance policies at Wyoming Medical Center (Casper) and Cheyenne Regional Medical Center may cover specialty drugs administered in outpatient infusion settings. Patients receiving Evenity injections in these facilities can apply for charity care that may cover all or part of the drug cost based on income-to-poverty ratio calculations.

"For patients with very high fracture risk, the cost of inaction often exceeds the cost of treatment. A single hip fracture generates $45,000 or more in acute care costs and frequently triggers loss of independence." This observation from the National Osteoporosis Foundation's Clinician Guide underscores why access programs exist [7].

Timeline and Practical Considerations for Wyoming Patients

Starting Evenity in Wyoming involves a defined sequence. After specialist evaluation and cardiovascular clearance, the prescriber submits a prior authorization (allow 5-14 business days). Upon approval, the specialty pharmacy ships the medication (2-5 business days). First injection occurs either at a clinic or after self-injection training.

The 12-month clock starts with dose one. Missing doses reduces efficacy. The FRAME extension study showed that bone mineral density gains from romosozumab dissipate without transition to an antiresorptive agent after the 12-month course [3]. Wyoming prescribers should have an alendronate or denosumab transition plan documented before initiating romosozumab.

Monitoring during treatment includes repeat DXA at month 12, serum calcium, and clinical assessment for injection site reactions (the most common adverse event at 5.2% incidence). Patients should report chest pain, leg swelling, sudden weakness, or slurred speech immediately given the cardiovascular boxed warning.

Monthly lab monitoring is not required by the FDA label, but many Wyoming endocrinologists check serum calcium and phosphorus at months 1, 6, and 12 given romosozumab's mechanism of sclerostin inhibition and its effects on mineral homeostasis.